We first determined the anti-proliferative effects of TMOC on human ovarian carcinoma cells, including A2780 (p53 wild-type), A2780/CDDP (cisplatin resistant subline of A2780, p53 mutant) and SKOV3 (p53 null) cells, as well as pre-neoplastic ovarian epithelial T29 cells. This evidence concerns the gene TP53 and ovarian carcinoma.